Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vedre, Ameeth
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.	Active, not recruiting	3	14013	Europe, Canada, US, RoW	Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml	Novartis Pharmaceuticals	Primary Prevention of Atherosclerotic Cardiovascular Disease	04/29	04/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure	Terminated	2	136	Europe, Japan, US, RoW	Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan	Novartis Pharmaceuticals	Heart Failure	11/24	11/24
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.	Completed	2	191	Europe, Japan, US, RoW	Experimental drug, Placebo	Novartis Pharmaceuticals	Resistant Hypertension	07/24	08/24
DETECT-HF, NCT06378632: AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM	Recruiting	N/A	500	Europe, US, RoW	Hearo App	Cordio Medical	Heart Failure	01/25	03/25